Abaloparatide

Summary

Abaloparatide (CHEMBL3301581) is an approved protein (ATC H05AA04) targeting PTH1R; indicated across 3 conditions including osteoporosis and postmenopausal osteoporosis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: H05AA04
• Targets: 1 (PTH1R)
• Indications: 3 conditions
• Clinical trials: 16

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3301581
Name	Abaloparatide
Type	Protein
Max phase	4
ATC	H05AA04

Also known as: Abaloparatida, Abaloparatide, BA-058, BA058, BIM-44058, Bim44058, Eladynos, Tymlos, ABALOPARATIDE

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
PTH1R	PTH1 receptor	Agonist		0.1%	Q03431

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Parathyroid hormone/parathyroid hormone-related peptide receptor.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PTH1R	10.7	EC50	0.02	nM	CHEMBL_ACT_18120915

Target pathways

Aggregated over 1 target gene(s): PTH1R.

Top Reactome pathways

2 total, by targets touching each:

Pathway	Targets	Genes
Class B/2 (Secretin family receptors)	1	PTH1R
G alpha (s) signalling events	1	PTH1R

Dominant GO biological processes

GO term	Targets
skeletal system development	1
in utero embryonic development	1
chondrocyte differentiation	1
osteoblast development	1
intracellular calcium ion homeostasis	1
cell surface receptor signaling pathway	1
G protein-coupled receptor signaling pathway	1
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	1
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	1
adenylate cyclase-activating G protein-coupled receptor signaling pathway	1
phospholipase C-activating G protein-coupled receptor signaling pathway	1
cell population proliferation	1
positive regulation of cell population proliferation	1
negative regulation of cell population proliferation	1
bone mineralization	1

Indications & clinical

Indications

3 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
osteoporosis	4	MONDO:0005298	EFO:0003882
postmenopausal osteoporosis	4	MONDO:0008159	EFO:0003854
bone fracture	2	MONDO:0005315	EFO:0003931

Clinical trials

Total trials: 16.

Phase distribution

Phase	Trials
PHASE2	7
PHASE3	4
PHASE4	3
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04467983	PHASE4	ACTIVE_NOT_RECRUITING	Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone
NCT04167163	PHASE4	COMPLETED	Abaloparatide Before Total Knee Arthroplasty
NCT04626141	PHASE4	WITHDRAWN	Supracondylar Distal Femur Fractures and Abaloparatide
NCT01343004	PHASE3	COMPLETED	Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women
NCT03512262	PHASE3	COMPLETED	Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)
NCT03710889	PHASE3	COMPLETED	Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption
NCT04064411	PHASE3	COMPLETED	Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis
NCT03841058	PHASE2	ACTIVE_NOT_RECRUITING	Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
NCT07587775	PHASE2	NOT_YET_RECRUITING	The Effect of Osteoporotic Medications on Vertebral Bone Quality Score
NCT00542425	PHASE2	COMPLETED	Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis
NCT01674621	PHASE2	COMPLETED	Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis
NCT03708926	PHASE2	WITHDRAWN	Effect of Abaloparatide on Lumbar Disc Degeneration
NCT04249232	PHASE2	COMPLETED	Abaloparatide and Pelvic Fracture Healing
NCT04760782	PHASE2	TERMINATED	PTH Analog Type II Odontoid Fracture
NCT03746041	PHASE1	COMPLETED	A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes
NCT04974723	Not specified	COMPLETED	Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

2 molecules share ≥1 primary target. Top 2 by shared-target count:

Molecule	Source	Status	Shared targets
TERIPARATIDE	ChEMBL	Phase 4 (approved)	PTH1R
Belzutifan	PubChem	Approved	PTH1R